Since the discovery of the association of HLA B27 with ankylosing spondylitis (Brewerton et al., 1973) an HLA association has been sought in rheumatoid arthritis (RA). This search has proved unsuccessful (Seignalet et al., 1972; Lies et al., 1972) except for the association between RA and B27 reported from Finland (Isomaki etal., 1975) . Recently, the emphasis has shifted from the HLA A, B, and C series to other identified genetic loci within the major histocompatibility complex on chromosome 6, such as the HLA D locus as defined by the mixed lymphocyte reaction (MLR). Evidence from studies in the mouse suggest that immune response (Ir) genes are present in this region of the complex (David, et al., 1973; Wernet, 1976) . Ir genes code for immune associated (Ia) antigens which are particularly expressed on the surface of B lymphocytes (Winchester et al., 1975) . Recently, multiple sclerosis has been found to have a strong association with such B cell alloantigens (Terasaki et al., 1976; Compston et al., 1976) .
In RA the presence of an antigen associated with the HLA D locus has been suggested because of weak MLR between homologous RA lymphocyte populations (Astorga and Williams, 1969; Stastny, 1974) . However, since this finding may be open to other interpretations (Keystone et al., 1976) we have Accepted for publication March 21, 1977 Correspondence to Dr. G. S. Panayi searched for an association between a B lymphocyte alloantigen and RA, and report one such strong association.
Patients
Forty-three patients were selected for study who had classical or definite RA (Ropes et al., 1959 (Weir, 1973) . Sera were sought which reacted more frequently with cells from RA patients than from normal individuals.
ABSORPTION OF SERA
Selected sera were absorbed with platelets to remove antibodies directed against HLA A, B, and C determinants. Sera were absorbed three times at 4VC using platelets obtained from the RA patients and controls used in the study, and from the Blood Transfusion Unit. A total of 1010 platelets per ml of serum was used. After absorption, sera were not cytotoxic for T lymphocytes. Alternative explanations for these results are possible. First, these antigens could be the cellsurface expression of virus infection of B lymphocytes. This seems untenable as one would have to postulate that three pregnancy sera selected at random detect three separate viral antigens present on B cells from normal individuals as well as patients with RA. Second, the increased frequency of cytotoxicity by M58 could be due to factors adsorbed on to the lymphocyte surface from RA sera. This also seems unlikely since reactivity with serum M58 was not related to disease activity and since 27 % of normal subjects also reacted with this serum. Furthermore one would have to assume that three such factors are present in RA and normal sera and are adsorbed on to B cells in order to account for the results. It appears therefore that the simplest explanation is that these sera do indeed detect alloantigens expressed on the surface of B lymphocytes.
The occurrence of M58 in only 74.4% of RA cases might have two explanations. The first is that M58 is not the true disease marker for RA but is closely linked to it so that as a result of linkage disequilibrium some 25% of RA patients do not possess this marker. Alternatively the disease termed 'RA' may represent a group of diseases of differing aetiology, not all of which are associated with M58.
The similar reactive patterns of sera M58 and M87 in the normal subjects need explanation. Two are possible. First that serum M87 contains a cross-reactive antibody of which there are many examples in HLA A, B, and C serology or, second, that it detects an antigen usually found in association with that defined by serum M58 (cf HLA Al and B8). The latter explanation seems more likely since the reactivity of RA lymphocytes with M87 is markedly reduced when compared to that of the normal subjects. It may be speculated that since the incidence of reactions with M58 is increased while that with M87 is decreased in RA patients, that these two sera may be detecting B cell alloantigens which are the product of an Ir gene complex.
We hope that family studies, investigations of disease subgroups, D-locus typing, and further alloantigen investigations will clarify the association of this antigen with RA. It may be concluded, however, that these results may indicate that a genetic basis exists for the development of RA.
